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Microfluidic organ-on-a-chip technology aims to replace animal
toxicity testing, but thus far has demonstrated few advantages over
traditional methods. Mitochondrial dysfunction plays a critical role in
the development of chemical and pharmaceutical toxicity, as well as
pluripotency and disease processes. However, current methods to
evaluate mitochondrial activity still rely on end-point assays, resulting
in limited kinetic and prognostic information. Here, we present a liver-
on-chip device capable of maintaining human tissue for over a month
in vitro under physiological conditions. Mitochondrial respiration was
monitored in real time using two-frequency phase modulation of
tissue-embedded phosphorescent microprobes. A computer-controlled
microfluidic switchboard allowed contiguous electrochemical mea-
surements of glucose and lactate, providing real-time analysis of
minute shifts from oxidative phosphorylation to anaerobic glycolysis,
an early indication of mitochondrial stress. We quantify the dynamics
of cellular adaptation to mitochondrial damage and the resulting
redistribution of ATP production during rotenone-induced mitochon-
drial dysfunction and troglitazone (Rezulin)-induced mitochondrial
stress. We show troglitazone shifts metabolic fluxes at concentrations
previously regarded as safe, suggesting a mechanism for its observed
idiosyncratic effect. Our microfluidic platform reveals the dynamics
and strategies of cellular adaptation to mitochondrial damage, a
unique advantage of organ-on-chip technology.
microfluidics | liver tissue engineering | toxicology | organ-on-a-chip
Microfluidic organ-on-a-chip devices offer an alternative toanimal experiments due to their ability to mimic physiological
parameters, such as shear or mechanical forces, acting on human
cells in vitro. Using a lung-on-chip device, Huh et al. (1) demon-
strated that mechanical forces are critical for the development of
nanoparticle toxicity in lung tissue, while our group and others
demonstrated the long-term maintenance of hepatocyte function in
a microfluidic bioreactor (2–5). Regretfully, most organ-on-chip
devices still rely on endpoint assays to assess drug toxicity, providing
limited dynamic information that can be used to assess the com-
pound mechanism of action (6, 7).
Mitochondrial function plays a critical role in the development
of disease and chemical toxicity (7, 8), as well as the regulation of
stem cell pluripotency (9). Mitochondrial dysfunction can occur
through direct damage to the respiratory chain, or through sec-
ondary mechanisms such as ER stress or lipid accumulation (10).
Because cells can adapt to loss of mitochondrial respiration by
using anaerobic pathways such as glycolysis and glutaminolysis
(Fig. 1A), mitochondrial damage can often go undetected with
disastrous clinical and financial consequences (8), which is a
particular concern in cultured cells that show an increased
reliance on glycolysis and glutaminolysis due to the Warburg ef-
fect. Thus, real-time monitoring of these metabolic fluxes could
provide critical insight into the development of mitochondrial
dysfunction, as well as loss and gain of mitochondrial function
in development.
Recently, we demonstrated the real-time measurement of oxygen
uptake in liver-on-chip devices using two-frequency phase modu-
lation of tissue-embedded phosphorescent microprobes (11). Oxy-
gen decreases phosphorescence decay time resulting in a phase
change that is independent of signal intensity. In contrast to other
methods, phase modulation is unaffected by focus distance or
changing microprobe concentration due to cell death or migration,
thus providing unparalleled ability to monitor oxygen uptake in
real-time. Our design offers clear advantage over Clark-type elec-
trodes that consume oxygen and require precise positioning and
frequent recalibration (12). However, oxygen measurements pro-
vide only circumstantial evidence to loss of mitochondrial function.
In this work, we report the development of a liver-on-chip device
capable of maintaining 3D aggregates of HepG2/C3A cells for over
28 d in vitro under physiological shear forces and stable oxygen
gradient mimicking the native liver microenvironment. Oxygen
uptake rate is monitored in real time using two-frequency phase
modulation, while a computer controlled microfluidic switchboard
automates washing, calibration, and amperometric measurements
of glucose uptake and lactate production over the same time pe-
riod (Fig. 1B). Our system permits the detection of minute shifts
from oxidative phosphorylation to glycolysis or glutaminolysis, in-
dicating mitochondrial damage in drug concentrations previously
believed to be safe. Our precise measurements permit a unique
analysis of the redistribution of ATP production in cells undergoing
mitochondrial stress and dysfunction, unraveling the unique dy-
namics of the metabolic adaptation to mitochondrial damage.
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Results
System Design.Mitochondrial dysfunction is a major cause of drug-
induced injury due to the limited ability of cells to generate ATP by
alternatives means. Increasing glycolysis, fermentation of glucose
to lactate, is the preferred route of energy production in the ab-
sence of oxygen (Fig. 1A). Glutamine degradation to lactate and
citrate, termed glutaminolysis, can also support tumor cell growth
under hypoxic conditions. Our hypothesis was that mitochondrial
damage would lead to rapid compensation, as cells shift from mi-
tochondrial respiration to glycolysis to survive. To monitor the
dynamic transition between these metabolic pathways, we designed
a microfluidic system that maintains growth-arrested HepG2/C3A
spheroids under physiological conditions while dynamically mea-
suring oxygen, glucose, and lactate concentrations (Fig. 1B).
Oxygen is measured using tissue-embedded microparticles
loaded with a ruthenium-based dye, whose phosphorescence is
quenched in the presence of oxygen leading to decreasing decay
time (Fig. 1C). In contrast to intensity measurement, decay time
is insensitive to probe concentration or excitation intensity. We
use sinusoidal intensity-modulated light, resulting in an oxygen-
dependent phase shift in the 605-nm emission (Fig. 1D). Using
our system, the signal is stable down to three particles, and
1.5 mm away from the microscope focus (11). In contrast to
optical measurements, electrochemical sensors require frequent
recalibration and demonstrate significant decay over time.
Therefore, we chose to integrate off-the-shelf medical-grade
sensors in our microfluidic design, and address them using a
computer-controlled microfluidic switchboard that sequentially
samples the bioreactor outflow, washes and recalibrates the
sensors. Our amperometric glucose and lactate sensors use
platinum electrodes to measure current under a polarization of
450 mV (Fig. 1E). Current is produced by the oxidation of glu-
cose or lactate to H2O2 by membrane-embedded glucose or
lactate oxidase (Fig. 1F). A single central processing unit (CPU)
controls the entire system, simplifying synchronization (13).
Design and Characterization of Hepatic Microwell Bioreactor. The
liver is highly vascularized, delivering oxygen at high rates while
protecting hepatocytes from the negative effects of shear (14,
15). The gradients that develop along the sinusoid induce a de-
marcation of function, termed metabolic zonation. To mimic this
environment we designed a polymethyl methacrylate (PMMA)
bioreactor with a detachable multiwell unit that permits cell
seeding in an open configuration (Fig. 2 A and B). HepG2/C3A
cells mixed with oxygen probes were seeded in the microwells
protecting the cells from the negative effect of shear forces while
providing a constant concentration of nutrients and removal of
metabolic waste products. Cells aggregate to spheroids after
overnight incubation (Fig. 2C), polarizing and reaching growth
arrest in 4–7 d in the presence of 1% (vol/vol) DMSO (16, 17).
Computational fluid dynamic modeling (Fig. 2D and E) showed
physiological shear forces under 0.03 Pa inside the microwells for
perfusion rates of 2 μL/min. The flow rate resulted in similar ox-
ygen concentration delivered to each well in the array (Fig. 2 D and
E). Oxygen consumption caused a gradient to develop along the
perfused spheroid, mimicking the in vivo microenvironment (Fig. 2E)
(18, 19). Glucose concentration showed a similar gradient, reaching
0.1 mM concentration at the bottom of the microwells. These results
suggest our reactor mimics aspects of the physiological microenvi-
ronment. Oxygen uptake was measured in real time over 28 d under
continuous perfusion (Fig. 2F). Measurement showed an increase in
oxygen uptake, stabilizing on day 4, suggesting the cells reached
steady state. Gene expression on day 30 of culture showed marked
elevation of liver-specific gene expression compared with static
culture (Fig. 2G). Primarily, expression of the Pregnane X receptor
(PXR) and the constitutive androstane receptor (CAR) increase by
10- and 18-fold, respectively (P < 0.024, n = 3), whereas their target
genes MDR1, CYP2C9, and CYP3A4 showed 20- to 300-fold in-
crease in mRNA abundance (P < 0.022, n = 3).
Real-Time Oxygen Measurement Shows Rapid Loss of Mitochondrial
Respiration. Rotenone is a widely used broad-spectrum organic
insecticide and pesticide, known to directly damage mitochondrial
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Fig. 1. (A) Schematic of glucose and glutamine utilization by central carbon metabolism. Theoretically, mitochondrial dysfunction will lead to a decrease in
oxygen uptake and increase in lactate production due to cellular shift from oxidative phosphorylation (purple) to glycolysis (orange). (B) Scheme of the
measurement setup. Bioreactor was loaded with tissue-embedded oxygen sensors and mounted on an Olympus IX83. OPAL unit controlled LED signal
modulation, exciting the oxygen sensors, and analyzed the signal through the photomultiplier readout. Bioreactor outflow was connected to a microfluidic
switchboard containing a series of pressure-controlled micromechanical valves. The switchboard introduced samples into a sensor unit containing electro-
chemical sensors for glucose and lactate. Sensors were controlled by a potentiostat (PSTAT). Optical, pressure, and electronic sensors were connected to a
single microprocessor that synchronized the signal. (C) Jablonski diagram describing the generation of phosphorescence with Ru-CPOx beads under the
influence of oxygen. The quenching of the phosphorescence by triplet oxygen leads to a decrease in signal intensity and phosphorescence decay time (T1).
(D) The effect described in C induces a phase shift between the intensity-modulated excitation and emission light. Thus, the degree of phase shift can be used
for determining the oxygen concentration. Two-superimposed frequencies were used to screen out background interference. (E) Design of amperometric
sensor in two-electrode configuration. Anodic oxidation of H2O2 on the platinum working-electrode (WE) held at 450 mV against the reference electrode
(REF/CE) produces a detected current. (F) H2O2 is created in equivalent amounts of the analyte as an intermediate product by the activity of glucose oxidase
(GOx) or lactate oxidase (LOx).
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complex I, inducing oxidative stress and apoptosis at low con-
centrations (20). Rotenone was perfused at concentrations of 1,
50, and 200 μM for 24 h, and oxygen uptake of the cells was
monitored in real time to assess cell viability and metabolic
function (Fig. 3A). Oxygen uptake dropped rapidly when cells
were exposed to 1, 50, and 200 μM rotenone, reaching 35%, 27%,
and 15% of normal respiration following 12-h exposure, re-
spectively. The majority of the effect occurred within the first
60 min, as expected from a direct complex I inhibitor. Plotting the
dose-dependent response of rotenone at 12 h, we calculate a TC50
of 12.5 μM in our system (Fig. 3B), compared with 2 μM in pri-
mary hepatocytes. To evaluate the toxicological end point of ro-
tenone, we quantified the number of intact and apoptotic nuclei
using the TUNEL assay (Fig. 3C). Cells exposed to rotenone
showed a 14 ± twofold increase in apoptosis (P < 0.001, n = 5), as
well as unlabeled cell death, suggesting necrosis.
Troglitazone is an antidiabetic and anti-inflammatory drug
that was removed from market due to severe drug-induced liver
injury (21). Though troglitazone mechanism of action is still
unclear, its metabolites were shown to block bile acid transporters
BSEP and MRP2, leading to cholestasis, whereas the parent
compound was shown to decrease mitochondrial membrane po-
tential (22). Troglitazone was perfused at concentrations ranging
from 50 to 2,000 μM for 24 h, and oxygen uptake of the cells was
monitored in real time to assess cell viability and metabolic func-
tion (Fig. 3D). Oxygen concentration at 50 μM troglitazone was
not significantly different from control. However, oxygen uptake
dropped when cells were exposed to 350, 500, and 2,000 μM
troglitazone, reaching 32%, 15%, and 8% of normal respiration
following 24-h exposure, respectively. Interestingly, most of the
effect occurred within the first 5 h, suggesting direct mitochondrial
damage rather than accumulation of secondary metabolites (11).
Plotting the dose-dependent response of troglitazone at 24 h, we
calculate a TC50 of 285 μM in our system (Fig. 3E), compared
with 100 μM in primary hepatocytes. To evaluate the toxico-
logical end point of troglitazone, we evaluated 5(6)-carboxy-2′,7′-
dichlorofluorescein (CDF) retention in treated and untreated cells
(Fig. 3F). Cells exposed to troglitazone showed a 4.5 ± 0.6-fold in-
crease in CDF staining due to inhibition of MRP2 (P < 0.001, n = 5).
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Fig. 2. (A) Explosive view of bioreactor components. From bottom to top: PMMA housing, cover glass, laser-cut PDMS microwells, top glass window, and
PMMA cover. (B) Photo of assembled bioreactor on microscope stage. (C) Composite tile scan image of HepG2/C3A organoid after overnight incubation with
embedded oxygen-sensing microprobes (orange). (D) Numerical simulation of the pressure drop and variations in oxygen concentration throughout the
bioreactor. (E) Cross-section of oxygen gradient developing due to consumption within the well (from top to bottom), mimicking the in vivo microenvi-
ronment. (Right) Gradients of glucose and lactate concentrations within the well. (F) Representative long-term oxygen measurement over 1 mo in bioreactor
perfused with cell culture medium at 2 μL/min. One hundred percent air represents atmospheric dissolved oxygen concentration (no consumption). Cultures
reach steady state within 4 d after seeding. (G) Log-scale quantitative gene expression analysis of HepG2/C3A cells in static culture compared with those
perfused with 1% DMSO for 30 d (growth arrest). PXR, CYP3A4 and CYP2C9 expression shows a 10-, 58-, and 300-fold increase in the bioreactor, respectively
(P < 0.024, n = 3). Values are within 10–30% of primary human hepatocytes. *P < 0.05 by Student’s t test.
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Overall, comparison of our bioreactor results to primary human
hepatocytes (IVIVC) across four drugs, including acetaminophen,
amiodarone, troglitazone, and rotenone showed an R2 of 0.99
(Fig. 3G). Interestingly, both rotenone and troglitazone showed a
dose-dependent time to onset of damage (Fig. 3H). Rotenone
acted within 6 min of administration at 0.2 mM, whereas troglita-
zone showed respiratory damage within 40–100 min. The dynamics
of these responses suggest that both compounds directly damage
the mitochondria, rather than produce a slow accumulation of toxic
intermediates. To evaluate this, we measured oxygen consumption
rates (OCR) of ADP-stimulated isolated mitochondria (Fig. 3I).
We show that troglitazone, like rotenone, can directly inhibit mi-
tochondrial respiration in minutes (P < 0.001, n = 3) in the absence
of enzymatic activation.
Automated Microfluidic Measurement of Glucose and Lactate. Elec-
trochemical sensors have a limited lifespan and require frequent
recalibration. Therefore, we fabricated an off-chip sensor unit
(Fig. 4A) containing off-the-shelf medical-grade sensors. Accurate
measurement required a sharp chemical gradient, which we achieved
by purging the system with air before each measurement, producing
a linear response of glucose and lactate sensors up to 20 mM
(Fig. 4B). To carry out the experimental steps automatically, we
fabricated a microfluidic switchboard containing 12 self-addressable
micromechanical valves (Fig. 4C) connected to a 32-bit ARM7-
based control unit that synchronizes flow, measurement, and
stimulation (13). Micromechanical valves were fabricated using
two-layer soft lithography showing an actuation pressure of 4 psi
and stability for over 15,000 cycles, 150–300 d at our sampling
rate (Fig. 4D). Bioreactors were continuously perfused with their
outflow split into a high-resistance waste and the valve-controlled
switchboard (Fig. 4E). Samples were obtained every hour by open-
ing the valve for 20 min and permitting a 40-μL sample to be in-
troduced into the sensor unit. Sampling was preceded and followed
by a 4-s purging with air (Fig. 4 E and F), creating a sharp concen-
tration step-change. A 200-s washing step was intertwined between
sampling and calibration steps. The entire sequence was 23.3 min
long, permitting a measurement of three bioreactors per hour.
At steady state, glucose and lactate concentration at the biore-
actor outflow were 2.9 mM and 5 mM, respectively (Fig. 4G andH).
Cell number was quantified by DNA content to be 105 cells/well,
resulting in glucose uptake rate of 2.4×10−9 mol·min−1 per 106 cells and
lactate production rate of 3 × 10−9 mol·min−1 per 106 cells under
steady-state conditions (Fig. S1). Each mole of glucose can produce
2 mol of lactate in anaerobic glycolysis, or use 6 mol of oxygen in
oxidative phosphorylation (Fig. 1A). Our results show a lactate over
glucose ratio of 1.3 for our cells, suggesting that 62% of glucose is
used in glycolysis. Together with our oxygen measurements (Fig. 2),
we suggest that 13% of glucose consumed is directed toward oxi-
dative phosphorylation with 26% directed toward other metabolic
pathways such as lipogenesis. To exclude fatty acid oxidation, we
measured their uptake rate in the bioreactor outflow. Fatty acid
uptake was 4.8 × 10−11 mol·min−1 per 106 cells, about 50-fold lower
than glucose uptake. Glutamine uptake was 1.6 × 10−10 mol·min−1
per 106 cells (Fig. S2), 10-fold lower than glucose uptake, suggesting
glutaminolysis had a minor contribution to the mitochondrial Krebs
cycle, which was predominantly using glucose as a source of energy
in steady state (Fig. 1A). We note that proliferating HepG2 cells
exhibit quite a different metabolic signature under static conditions,
showing lactate over glucose ratio ranging from 1.8 to 2.
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Fig. 3. (A) Representative oxygen uptake over time
response of HepG2/C3A cells exposed to increasing
concentrations of rotenone. (B) Dose dependence of
rotenone after 12 h. TC50 was calculated to be
12.5 μM. (C) TUNEL staining shows 14-fold increase in
apoptosis following 24 h exposure to 200 μM rote-
none (P < 0.001, n = 5), as well as unlabeled cell
death, suggesting necrosis. (D) Representative oxy-
gen uptake over time response of HepG2/C3A cells
exposed to increasing concentrations of troglita-
zone. (E) Dose dependence of troglitazone after
24 h. TC50 was calculated to be 285 μM. (F) CDFDA
staining shows 4.5-fold increase in intracellular ac-
cumulation of bile acids (cholestasis) following 24-h
exposure to 200 μM troglitazone (P < 0.001, n = 5).
(G) IVIVC curve comparing TC50 values of primary
human hepatocytes to our bioreactor showing an
excellent R2 = 0.99 correlation for acetaminophen,
amiodarone, troglitazone, and rotenone. (H) Time
to onset of mitochondrial damage was dose de-
pendent for both rotenone (Left) and troglitazone
(Right), occurring in minutes rather than hours fol-
lowing exposure to the drugs. (I) OCR measured on
isolated mitochondria for 30 min, followed by ADP
injection (arrow) and subsequent injection of 50 μM
rotenone (Left) or troglitazone (Right). Loss of OCR
was immediate (P < 0.001, n = 3) and did not require
cytosolic enzyme activation of the drugs. **P < 0.01
by Student’s t test.
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Dynamics of Drug-Induced Mitochondrial Dysfunction.Drug-induced
mitochondrial dysfunction is often overlooked due to the ability
of cells to circumvent damaged metabolic pathways at low drug
concentrations, and secondary effects, such as apoptosis becoming
dominant at increasing concentrations. To characterize the dynamics
of mitochondrial dysfunction, we exposed the cells to low concen-
trations of rotenone or troglitazone. Rotenone is a direct inhibitor of
mitochondrial respiration, reducing oxygen uptake by 80% (Fig. 3 A
and B) but inducing less than 15% cell death at 50 μMconcentration
(Fig. 5A). Real-time glucose and lactate measurements showed a
sharp 59% drop in glucose uptake mirrored by a 35% drop in lactate
production within the first 2 h (Fig. 5B). Lactate over glucose ratio
increased from 1.5 to 2.6, demonstrating a strong shift toward gly-
colysis, coupled with a rapid loss of oxygen uptake (Fig. 5C). Cellular
death became apparent after 6 h of exposure to rotenone, with an
additional 65% drop in glucose uptake, but surprisingly no change in
lactate production. Lactate over glucose ratio increased from 2.6 to
6.1, suggesting that glucose was no longer the main source for lactate
production as the cells shifted toward glutaminolysis while drifting
toward apoptosis (Fig. 3C). Indeed, offline measurement showed
30 ± 4-fold increases in glutamine consumption (Fig. S2) following
rotenone exposure (P < 0.007, n = 3).
At 50 μM concentration, troglitazone reduced oxygen uptake
rate by 10% (Fig. 3 D and E), while cell viability was not signifi-
cantly different from untreated control (Fig. 5D). Surprisingly,
though glucose uptake remained relatively unchanged, lactate
production increased by 51% within 4–5 h (Fig. 5E). Lactate over
glucose ratio increase from 1.3 to 1.8, demonstrating a clear shift
toward glycolysis at concentrations below the threshold of trogli-
tazone toxicity (Fig. 5F). Offline measurement showed a mild 5 ±
2-fold increase in glutamine consumption (Fig. S2) following
troglitazone exposure (P < 0.04, n = 3).
Metabolic Adaptation and Redistribution of ATP Production. Our
results demonstrate differential metabolic response to mild or
severe damage to the respiratory chain, exemplified by troglita-
zone and rotenone exposure, respectively (Figs. 5–7). Because the
flux balance stoichiometry is known (Methods), our data allows us
to estimate intracellular fluxes (Table 1) and predict ATP pro-
duction under each condition (Fig. 5G).
Troglitazone-induced mitochondrial stress caused a 23% de-
crease in oxidative phosphorylation and 51% increase in glycolysis
after 6 h of exposure (Table 1). Glucose was no longer directed
toward other metabolic pathways (Fig. 7) and was entirely used for
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Fig. 4. (A) Photo of PMMA unit housing both glu-
cose and lactate sensors with total internal volume
of 26 μL. (B) Amperometric calibration curves of
glucose and lactate sensors in the PMMA housing.
Measurements were carried out under static condi-
tion for 100–200 s. Air purging before sample in-
troduction ensured sharp change in chemical gradient.
(C ) Photo of two-layer microfluidic switchboard
containing flow channels (red) and independently
addressed control channels (blue). (D) Characteriza-
tion of micromechanical valve switching pressure as a
function of number of cycles (age). Valves withstand
over 15,000 cycles without loss of sensitivity, up to
300 d of continuous operation. (E) Schematic of
microfluidic switchboard connectivity and operating
sequence. Switchboard contained inputs to air,
washing buffer (PBS), and calibration solution. Bio-
reactors outflow was split to high-resistance waste
(W) and normally closed channel to switchboard. Air
purging was carried out for 4 s before and after
measurement or calibration step. A total of 200 s
of washing intersected between measurements.
(F) Images of perfusion sequence starting with a wash-
ing step (blue), air purging, and sample introduction
(red). (G) Photo of simplified setup where a single bio-
reactor is connected to the switchboard. (H) Automatic
amperometric calibration and measurement of glucose
concentration in bioreactor outflow.
Table 1. Calculated metabolic fluxes in nmol·min−1 per 106 cells for untreated cells (normal),
troglitazone-treated cells (mitochondrial stress), and rotenone-treated cells (mitochondrial
dysfunction)
Condition Glycolysis Respiration Glutaminolysis Lipogenesis
Normal 1.49 0.31 0 0.62
Mitochondrial stress 2.25 0.25 0.02 0
Mitochondrial dysfunction 0.97 0.03 0.56 0
Total glucose uptake rate was 2.4 nmol·min−1 per 106 for untreated cells, 2.5 nmol·min−1 per 106 for
troglitazone-treated cells, and 1.0 nmol·min−1 per 106 for rotenone-treated cells.
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ATP production (Fig. 5 G and H). These metabolic shifts, to-
gether with mild up-regulation of glutaminolysis (Fig. S2), allowed
troglitazone-treated cells to maintain 97% of ATP production of
untreated cells (Fig. 5G). Direct measurement of ATP/ADP ratio
confirms our predictions (Fig. 5G).
In contrast, rotenone-induced mitochondrial dysfunction caused
a 90% decrease in oxidative phosphorylation flux and 34% increase
in glycolysis after 3 h of exposure (Table 1). Moreover, lactate
production outpaced glucose uptake, suggesting glutaminolysis
started playing a role in energy production, confirmed by offline
measurements of glutamine uptake (Fig. 7; Fig. S2). Despite these
metabolic shifts, ATP production of rotenone-treated cells was less
than 36% of untreated cells (Fig. 5G and H). Direct measurement
of ATP/ADP ratio confirms our predictions (P < 0.001, n = 3).
Pathway Validation Under Static Conditions. To confirm our findings,
we exposed static cultures of HepG2/C3A cells to 50 μM of rote-
none and troglitazone and stained for mitochondrial membrane
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Fig. 5. (A) Composite tile scan image of live/dead staining of HepG2/C3A organoids in bioreactors treated for 24 h with 50 or 200 μM rotenone. Approximately
15% of the cells died following exposure to 50 μM rotenone. (B) Representative curves of oxygen uptake, glucose uptake, and lactate production of HepG2/C3A
cells following exposure to 50 μM rotenone (dotted line). Glucose uptake is shown as inlet–outlet concentration (red circles), whereas lactate production is
shown as outlet–inlet concentration (green squares). (C) Changes in lactate over glucose ratio following exposure to rotenone (dotted line). Ratio shifts from 1.5
to 2.6 within 3 h after exposure, indicating a shift from oxidative phosphorylation to glycolysis. Ratio spirals to 6.1 after 6 h exposure followed by increase in cell
death. (D) Composite tile scan image of live/dead staining of HepG2/C3A organoids in bioreactors treated for 24 h with 50 or 200 μM troglitazone. Less than 5%
of the cells died following exposure to 50 μM troglitazone, not significantly different from control. (E) Representative curves of oxygen uptake, glucose uptake,
and lactate production of HepG2/C3A cells following exposure to 50 μM troglitazone (dotted line). (F) Changes in lactate over glucose ratio following exposure
to troglitazone (dotted line). Ratio gradually shifts from 1.3 to 1.8 within 6 h after exposure, indicating a shift from oxidative phosphorylation to glycolysis.
(G) Relative ATP production rate calculated from flux balance analysis (Table 1; Methods), juxtaposed with experimentally measured ATP/ADP ratio in tro-
glitazone-, rotenone-, and vehicle-treated cells. Rotenone-treated cells show 47% decrease in ATP/ADP ratio (P < 0.001, n = 3), whereas troglitazone-treated
cells show no significant difference despite the metabolic shift. (H) Diverging metabolic sources of ATP production in untreated cells (normal), troglitazone-
treated cells (mitochondrial stress), and rotenone-treated cells (mitochondrial dysfunction) presented as pie charts of relative diameter.
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potential (MMP) at regular intervals (Fig. 6A). Cells showed a
rapid 40 ± 6% increase in MMP within 3 h of exposure to ro-
tenone (P < 0.001, n = 3), but signal was rapidly lost due to cell
death within 6 h. In contrast, exposure to troglitazone showed
a steady 33 ± 7% increase in MMP over 6 h of exposure (P <
0.001, n = 3; Fig. 6B).
To demonstrate that altered MMP leads to the observed changes
in metabolic pathways we used the Seahorse Flux Analyzer to
measure changes in oxidative phosphorylation, glutaminolysis, and
glycolysis on cells exposed to 50 μM of rotenone and troglitazone
for 6 h (Fig. 6 C–E). As could be expected, rotenone induced
83± 5% decrease in mitochondrial basal metabolic rate (P < 0.0002,
n = 3) and 85 ± 8% decrease in oxidative phosphorylation (P <
0.0005, n = 3). Glutaminolysis increased 4 ± 1 fold (P < 0.03,
n = 3; Fig. 6D), whereas glycolytic capacity was relatively un-
changed (Fig. 6E). Changes induced by troglitazone were
milder, resulting in a 20 ± 6% decrease in mitochondrial basal
metabolic rate (P < 0.01, n = 3), but no significant changes in
glutaminolysis or glycolysis could be measured under static
conditions, although both fluxes showed a mild up-regulation
(Fig. 6 D and E).
Discussion
In this work we established a robust microfluidic platform com-
bining liver-on-chip technology with automated microfluidic anal-
ysis of glucose metabolism and mitochondrial function (Fig. 1). Our
system uses 1% DMSO to growth-arrest self-assembled aggregates
of HepG2/C3A cells maintained under physiological conditions
(Fig. 2). Cultures stabilized within 4 d displaying strong elevation of
CYP450 expression (Fig. 2 F and G) and MRP2-active apical
surfaces (Fig. 3F). At steady state, 13 ± 5% of the glucose con-
sumed by growth-arrested HepG2/C3A cells in our bioreactor was
directed toward oxidative phosphorylation with minor to negligible
contributions from glutamine and lipid oxidation.
One advantage of our platform is the integration of medical-
grade commercial sensors in a modular off-chip unit. These off-
the-shelf components dramatically reduce fabrication costs and
can be replaced as needed without pausing the experiment; this is
particularly important with electrochemical sensors whose activity
is dependent on membrane integrity and enzymatic function. Off-
chip measurement also allowed us to automate sensor calibration,
and create sharp chemical gradients, ensuring measurement sta-
bility for several days in culture, which stands in contrast to prior
reports of integrated on-chip glucose and lactate sensors that offer
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Fig. 6. (A) Live staining of HepG2/C3A cells with JC1 dye following exposure to 50 μM rotenone (Upper) or troglitazone (Lower). (B) Rotenone causes
significant increase in MMP after 3 h of exposure (P < 0.001. n = 3). Troglitazone causes a gradual increase in MMP along 6 h of exposure (P < 0.001, n = 3). (C)
Direct measurement of OCR using a Seahorse XF24 analyzer on HepG2/C3A cells exposed to 50 μM troglitazone, rotenone, or vehicle control. Basal respiration
(blue) was measured for 30 min, showing significant differences between the three conditions (P < 0.001, n = 3). Oligomycin was injected at 30 min, blocking
ATP production due to oxidative phosphorylation (red). FCCP was injected at 60 min, followed by complex I and III inhibitors at 90 min, showing differences in
maximal mitochondrial capacity (green). (D) Troglitazone induced 20 ± 6% decrease in basal metabolic rate (P < 0.01, n = 3) and a 22 ± 9% decrease in
maximal mitochondrial capacity (P < 0.05, n = 3) following FCCP injection. Rotenone induced 85 ± 5% decrease in oxidative phosphorylation (P < 0.001, n = 3)
and 83%, 87% in basal and maximal capacity as well. Glutamine oxidation rate (glutaminolysis) is juxtaposed to the right showing nonsignificant 26 ± 30%
increase following troglitazone treatment, but a 382 ± 115% increase due to rotenone exposure (P < 0.03, n = 3). (E) Extracellular acidification rate (ECAR), a
surrogate measure of lactate production, increased by 43 ± 43% in troglitazone-treated cells, and decreased 21 ± 12% in rotenone-treated cells (P > 0.17, n =
3). *P < 0.05, **P < 0.001 by Student’s t test.
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less than 1–3 h of operation before signal drift requires recali-
bration (23). Stability of our sensors permitted over 24 h of
continuous sampling (Fig. 5). In fact, though oxygen uptake
dropped within minutes after exposure to rotenone and troglita-
zone (Fig. 3H), the metabolic shift from oxidative phosphorylation
to glycolysis occurred only after 3 and 6 h of exposure, respectively
(Fig. 5 C–F). Analysis of MMP showed a similar time frame and a
gradual loss of function, coupled with a gradual change in glucose
and lactate fluxes, suggesting that enzymatic rather than tran-
scriptional changes are responsible for the metabolic shift. Change
in glycolytic enzyme acetylation due to acetyl-CoA accumulation is
one putative mechanism that requires further investigation.
A second advantage of our platform is the optical measurement
of oxygen using tissue-embedded microsensors (Fig. 1). Optical
sensors are advantageous over Clark-type electrodes because the
latter consume oxygen during measurement and require frequent
recalibration (12). Whereas standard optical sensors are affected by
changes in optical focus, background, or particle migration, our ap-
proach focused on measurement of a phase-shift that is independent
of changes in signal amplitude (11). Processes such as cell migration
and necrosis that change the number and location of microbeads
during the experiment have no effect on our measurement, per-
mitting continuous measurements of oxygen uptake for over 28 d in
vitro (Fig. 2F). In fact, our ability to measure oxygen uptake rates
during stable stimulation stands in contrast to other approaches in
the field that either circulate medium to increase signal intensity (24)
or measure under static conditions (25) rather than at steady state.
The integration of both sensing modalities allowed us to identify
differences in the metabolic response to rotenone and troglitazone
that appear to be related to the severity of mitochondrial damage.
Exposure to the antidiabetic drug troglitazone (Rezulin) induced
the expected response as cells diverted glucose from metabolic
pathways such as lipogenesis toward lactate, maintaining 97% of
cellular ATP production and normal ATP/ADP ratio (Fig. 5G).
This switch was not previously detected because the Warburg effect
often dominates cell metabolism in culture and cell viability is un-
affected. Though drug effect at this concentration appears minor, it
could lead to an idiosyncratic response in compromised patients.
In contrast to the troglitazone response, cellular adaptation to
rotenone-induced mitochondrial dysfunction was surprising. Cells
showed a 59% decrease in glucose uptake, suggesting an accumu-
lation of intermediates led to a block in downstream glycolysis. The
switch to compensatory mechanisms was gradual, because lactate
over glucose ratio increased above 2, and glutamine uptake in-
creased, demonstrating a shift toward glutaminolysis (Fig. 6 C–E).
Our results demonstrate the importance of monitoring all three
fluxes because no combination of two measurements could reveal
the entire picture.
In conclusion, our work demonstrates real-time measurement
of glucose, lactate, and oxygen in a liver-on-chip bioreactor perfused
under physiological conditions. Growth-arrested HepG2/C3A cells
demonstrate long-term gene expression, polarization, and mito-
chondrial function for over 28 d in vitro. Automated electrochemical
measurements are demonstrated for over 24 h in vitro. Our mea-
surement allowed us to detect minute changes in the utilization of
glucose occurring within 3 and 6 h after exposure to rotenone and
troglitazone, respectively. The platform is uniquely able to monitor
metabolic changes indicating mitochondrial dysfunction occurring at
drug concentrations previously regarded as safe, as well as re-
distribution of ATP production under multiple conditions.
Materials and Methods
Bioreactor Fabrication. Bioreactors were fabricated from PMMA using computer
numerical control (CNC) machining. Each unit was composed of two 50.8-mm
circular support structures that fit standard 2-inch inserts, containing glass win-
dows for microscopy. The bioreactor housed a removable polydimethylsiloxane
(PDMS) microwell insert in which cells are protected from the negative effect of
shear. Sealing around the microwells was realized with a rubber gasket creating
an internal volume of 40 μL.
Removable Microwell Insert. PDMSmicrowell inserts were fabricated using laser
cutting. Briefly, a thin sheet of PDMS (Dow Corning) was cast to 0.7 mm height
using a motorized film applicator (Erichsen) and cured at 70 °C for 1 h.
Microwells were cut to 1.5 mm diameter, and a center-to-center distance of
3 mm using a 355-nm pulsed Nd-YAG laser (3D-Micromac). PDMS inserts were
washed with 70% (vol/vol) EtOH, nitrogen dried, and covalently bound to clean
0.5-mm thick glass coverslips (Schott) using oxygen plasma activation.
Cell Culture. HepG2/C3A cells were cultured under standard conditions in a hu-
midified incubator at 37 °C, under 5% CO2. Cells were obtained from the
American Type Culture Collection. Cells were cultured in low-glucose modified
Eagle medium supplemented with 10% (vol/vol) FCS, 100 U/mL penicillin, and
100 μg/mL streptomycin (Sigma-Aldrich). Mediumwas supplemented with 1%DMSO
following bioreactor seeding to induce growth arrest and differentiation (16, 17).
Bioreactor Seeding. PDMSmicrowell inserts were sterilized with 70% EtOH and
30-min exposure toUV light before cell seeding. Cellswere trypsinized, counted,
and centrifuged at 300 × g for 5 min at 4 °C. The pellet was then mixed with
400 μg CPOx-50-RuP oxygen-sensing beads (Colibri Photonics) and resuspended
in 100 μL of ice-cold solution of collagen type I (BD Biosciences) for a final
seeding density of 4 × 106 cells/mL. The PDMS microwell insert was placed on
ice and coated with ice-cold collagen solution for 5 min to remove air bubbles.
Then 100 μL of collagen type I suspension containing cells and oxygen-sensing
beads was layered on top the wells and incubated for 10 min on ice. The low
temperature prevented premature collagen polymerization and the induction
of cellular stress response pathways. Afterward, excess cell and microbead
suspension was gently wiped off the microwell insert using a sterile glass
coverslip leading to a concentration of 100,000 cells and 20 oxygen-sensing
beads per well. Variance in cell density between individual wells and between
bioreactors was less than 10% measured by DNA content. The inoculated
microwell insert was then incubated for 5 min at 37 °C to polymerize the
collagen. Following polymerization, the insert was immersed in 5 mL of cell
culture medium and incubated for 20 min at 37 °C before being sealed in the
bioreactor housing. Bioreactors were then placed in a climate control chamber
(Evotec) on an IX81 fluorescence microscope (Olympus). Bioreactors were
continuously perfused with cell culture medium noted above supplemented
with 10 mM Hepes and 1% DMSO at a flow rate of 2 μL/min. The automated
and motorized microscope stage was equipped with a holder for three
microreactors, allowing three experiments to run simultaneously.
Quantitative RT-PCR. RNA was isolated and purified using Macherey–Nagel
NucleoSpin RNA II kit according to manufacturer instructions. RNA concentration
and purity was determined using NanoDrop ND-1000 spectrophotometer
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Fig. 7. Schematics depicting the metabolic response of liver cells to trogli-
tazone-induced mitochondrial stress and rotenone-induced mitochondrial
dysfunction compared with untreated controls. Down-regulated fluxes are
shown in green, up-regulated fluxes are shown in red. Numbers reflect
measured changes in glucose, lactate, and oxygen uptake.
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(Thermo Fisher Scientific). cDNA was synthesized from 1 μg RNA sample using
qScript cDNA SuperMix (Quanta BioSciences) according to the manufacturer’s
protocol. Gene expression analysis was carried out using KAPA SYBR FAST Uni-
versal 2× qPCR Master Mix (Kapa Biosystems) on BioRad CFX96 Real-Time System,
according to manufacturer’s directions. Gene transcription was evaluated using
theΔΔCt method normalized to 60S ribosomal protein L32 (RPL32) or ubiquitin C.
Finite Element Analysis.A computational fluid dynamicmodelwas used tomodel
pressure distribution, oxygen supply, and glucose consumption rates within the
microwell bioreactor. A 3D model of the bioreactor geometry was designed and
meshed using an extremely fine mesh of 5-μm tetrahedral elements. Finite
element simulations were carried out using COMSOL Multiphysics 4.3b, coupling
the Navier–Stokes equations with the convection and diffusion model for
transport of oxygen and glucose. Inlet oxygen concentration was atmo-
spheric 0.2 mM with a diffusion coefficient of 1.8 × 10−9 m2/s. Oxygen uptake
rate was measured to be 1.8 × 10−9 mol·min−1 per 106 cells. Inlet glucose con-
centration was 5.5 mMwith a diffusion coefficient of 6 × 10−10 m2/s, and uptake
rate was measured under steady-state condition to be 2.4 × 10−9 mol·min−1 per
106 cells. Inlet lactate concentration was measured to be 1.5 mM, and production
rate was measured to be 3 × 10−9 mol·min−1 per 106 cells under steady-
state conditions.
Chemical Compounds. Troglitazone (T2573) and rotenone (R8875) were pur-
chased from Sigma-Aldrich and diluted fromH2O or DMSO stock concentration
1:1,000 into HepG2/C3A culture medium. Exposure onset was calculated to
within ±1 min based on volumetric flow rate, considering the length of the
tubing and bioreactor volume.
Real-Time Oxygen Measurement. Real-time oxygen measurements were per-
formed optically using lifetime-based luminescence-quenching as previously
described (11). Briefly, 50-μm diameter polystyrene microbeads were loaded
with ruthenium– phenanthroline-based phosphorescence dye (CPOx-50-RuP)
that shows a decrease in phosphorescence decay time as a function of oxygen
concentration (Fig. 1C). Excited by a sinusoidal amplitude-modulated 532-nm
LED source, the microbeads emit a sinusoidal amplitude-modulated light at
605 nm that is shifted in phase due to oxygen quenching (Fig. 1D). To over-
come the superposition of in-phase background fluorescence that alters the
phase of the detected signal, we used a 53.5-kHz and 31.3-kHz two-frequency
phase modulation, which allowed us to screen out background interference
(26–28). Measurements were carried out by averaging five consecutive 3-s
exposures, followed by 17-s intervals, for a total of 100 s. Measurements were
taken every 15 min for as long as 28 d with no phototoxicity, signal drift, or
relevant loss of signal intensity. The apparatus consists of the OPAL package
(Colibri Photonics) that is comprised of a control module, 532-nm LED, and a
photomultiplier detector mounted on the ocular of an IX83 Olympus micro-
scope (Olympus). A filter cube with 531/40 (excitation), 607/70 (emission) was
inserted in the optical light path during measurements.
Evaluation of Toxicological End Points. PMDS microwell inserts were removed
from the bioreactor following 24-h exposure to rotenone or troglitazone.
Cholestasis was evaluated using 5(6)-carboxy-2′,7′-dichlorofluorescein diacetate
(CDFDA) cell-permeable dye that is metabolized to fluorescent CDF and se-
creted to active bile canaliculi by active multidrug resistance-associated protein
2 (MRP2). Briefly, cells were incubated with 2 μg/mL of CDFDA and 1 μg/mL of
Hoechst 33342 for 20 min, and washed with PBS. Number of bile canaliculi foci
was normalized for number of Hoechst-labeled nuclei. Apoptosis was evaluated
using DeadEnd fluorometric TUNEL system (Promega) according to manufac-
turer directions. Briefly, cells were fixed in 4% (wt/vol) paraformaldehyde,
permeabilized, and exposed to fluorescein-12-dUTP and terminal
deoxynucleotidyl transferase, dyeing apoptotic nuclei green. The reaction
was subsequently stopped and the cells counterstained for Hoechst. A
percent apoptotic nucleus was calculated by dividing the number of TUNEL
to Hoechst-positive nuclei.
Measurement of Mitochondrial Stress in Isolated Mitochondria. Mitochondria
were isolated using a Mitochondria Isolation Kit (Abcam) per manufacturer in-
structions. Briefly, 107 cells were collected and ruptured using 30 strokes in a
precooled dounce homogenizer. Homogenate was centrifuged twice at 1,000 ×g
for 10 min at 4 °C to remove debris, and finally at 12,000 × g for 15 min at 4 °C.
Pellet containing the isolated mitochondria was resuspended in a protease in-
hibitor mixture. Protein concentration was determined using Bradford. A total of
20 μg of mitochondrial protein per well was plated in gelatin-coated SeaHorse
XFp cell culture miniplate and centrifuged at 3,000 × g for 20 min at 4 °C in
mitochondrial assay solution as previously described (29). Oxygen consumption
rate (OCR) was measured by the XFp Extracellular Flux Analyzer (Seahorse Bio-
sciences). Mitochondrial activity was profiled by successive injections of ADP
(Sigma-Aldrich) and 50 μM of troglitazone, rotenone, or DMSO control.
Microfluidic Switchboard Fabrication. A computer-controlled microfluidic switch-
board carried out automated sampling, calibration, and washing of the am-
perometric sensor unit, fabricated using two-layer soft lithography. Briefly,
an adherent layer of hexamethyldisilazane (Sigma-Aldrich) was spin coated at
4,000 rpm for 30 s. Four layers of AZ-4652 (MicroChem) were sequentially spin
coated at 800 rpm for 40 s, baked for 5 min at 100 °C, and exposed to UV light
for 90 s. Curved AZ-4652 flow channels were molded by reflow using a gradual
temperature increase of 35 °C to 150 °C over 3 h followed by hard-baked
overnight at 150 °C. AZ-4652 channels dimensions were measured to be 100 ×
25 μm (width × height). Control layer was fabricated separately using SU-8
photoresist (MicroChem), spin coated to 100-μm height, prebaked for 25 min at
100 °C, exposed to UV light for 15 s, and postbaked for 12 min. Top layer SU-8
control channels dimensions were 100 × 100 μm (width × height). Master molds
were treated with trichlorosilane (Sigma-Aldrich) for easier removal of PDMS
after curing. Each layer was cast separately by replica molding, aligned, and
bonded via curing agent diffusion as previously described (30). The microfluidic
switchboard was finally bonded to glass using oxygen plasma activation. The
final device consists of 11 inlets and a common outlet that are regulated by self-
addressable micromechanical valves.
Flow System and Microcontroller. Dedicated microfluidic controller and flow
circuit was previously described in detail (13). Briefly, digitally controlled so-
lenoid valves (Festo) were assembled into two pressure manifolds with a linear
range of 0.15–6 bars. One manifold was connected to fluid reservoirs (Fluigent)
perfusing the bioreactor, washing solution, atmospheric air, and calibration
buffers. The second manifold was used to actuate the switchboard’s control
channels with a pressure of 1.05 bar. The switchboard flow outlet was con-
nected to the PMMA housing of the amperometric sensors unit.
Real-Time Glucose and Lactate Measurements. Amperometric glucose and
lactate sensors were purchased from BioSensor Technology and embedded in a
CNC-fabricated PMMA flow-chamber with an inner volume of 26 μL. The
sensors are based on the enzymatic reactions of glucose oxidase, with a linear
range of 0.5 mM to 30 mM, and lactate oxidase, with a linear range of 0.5 mM
to 20 mM. Both sensors produce H2O2 in amounts proportional to the mea-
sured metabolite, which is detected with platinum electrodes under polarized
condition. The microfluidic controller (13) was programmed to open a micro-
fluidic valve every hour, allowing a 40-μL medium sample to flow through the
switchboard and into the sensors unit. Amperometric measurement lasted 200 s
and was followed by automated perfusion of PBS washing solution, CAL 4+M
calibration buffer (Eschweiler), and 4 s of air bubble acting as a diffusion barrier
between samples. Reading was carried out on EmStat3 OEM embedded
potentiostat (PalmSens) connected to the central computer.
Assessment of Cell Viability. Unless otherwise noted, cell viability was de-
termined using a LIVE/DEAD Cytotoxicity kit (Molecular Probes) according to
manufacturer’s instructions. In brief, cultures were incubated with 2 μM Cal-
cein AM and 3 μM ethidium homodimer-1 for 25 min. Hydrolysis by functional
intracellular esterases causes live cells to fluoresce green, while the punctured
membranes of dead cells permit ethidium homodimer-1 to bind DNA and
fluoresce red. Cellular viability was calculated by live to dead ratio and nor-
malized to negative control.
Quantification of ATP/ADP Ratio. Intracellular ATP and ADP quantification was
carried out using Abcam ADP/ATP Assay Kit (ab65313) according to manu-
facturer’s instructions. Briefly, reaction buffer was preincubated at room
temperature for 2 h before beginning of measurements, to burn off low-level
ATP contamination, as suggested by the manufacturer. Cells were incubated in
nucleotide releasing buffer for 5 min at room temperature, with gentle
shaking. Background bioluminescence reading of the reaction mix was taken
for calibration, followed by 2 min incubation of 50 μL sample solution in each
reaction well, and a bioluminescence reading to measure cellular ATP content.
ADP converting enzyme was then added, as instructed, following incubation
of 2 min at room temperature to measure total ADP + ATP.
Measurement of Oxidative Phosphorylation and Mitochondrial Stress. HepG2/
C3A cells were plated in gelatin-coated SeaHorse XFp cell culture miniplates
(Seahorse Bioscience) and cultured for 24 h. Subsequently, cultures were
treated with medium containing 50 μM troglitazone for 6 h, 50 μM rotenone
for 3 h, or vehicle control before initiation of assay. Mitochondrial stress test
assay was conducted per manufacturer instructions (29). Briefly, cells were
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incubated in unbuffered XF Base Medium supplemented with 2 mM gluta-
mine, 1 mM sodium pyruvate, and 10 mM glucose (pH 7.4) for 1 h at 37 °C in a
non-CO2 incubator. Basal OCR was measured for 30 min, followed by injection
of 1 μM oligomycin, a mitochondrial complex IV inhibitor that completely
blocks oxidative phosphorylation. The decrease in OCR due to oligomycin
treatment is defined as oxidative phosphorylation rate. A total of 1 μM car-
bonyl cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP), an uncoupling
agent, is added at 60 min to measure maximal mitochondrial activity followed
by complete inhibition at 90 min using a mixture of 0.5 μM antimycin A and
rotenone, mitochondrial complex III and complex I inhibitors. Basal extracel-
lular acidification rates (ECAR) was measured for 30 min, in the presence of
10 mM glucose, followed by injection of 1 μM oligomycin. The increase in
ECAR due to oligomycin treatment was defined as glycolytic capacity. Data
are presented normalized to 106 cells as determined by Hoechst DNA
content assay.
Measurement of Glutamine Oxidation. HepG2/C3A cells were plated in gelatin-
coated XFp cell culture miniplates and cultured for 24 h. Subsequently, cultures
were treated with medium containing 50 μM troglitazone for 6 h, 50 μM ro-
tenone for 3 h, or vehicle control before initiation of assay. Glutamine oxi-
dation assay was conducted per manufacturer instructions. Briefly, cells were
incubated in unbuffered XF Base Medium supplemented with 2 mM gluta-
mine, 1 mM sodium pyruvate, and 10 mM glucose (pH 7.4) for 1 h at 37 °C in a
non-CO2 incubator. Glutamine oxidation was profiled by successive injections
of 3 μM BPTES, an allosteric inhibitor of glutaminase (GLS1), and a mixture of
4 μM etomoxir, a carnitine palmitoyl-transferase 1A (CPT1A) inhibitor and
2 μM UK5099, a mitochondrial pyruvate carrier inhibitor, blocking fatty acid
oxidation and oxidative phosphorylation, respectively. The decrease in base-
line OCR due to BPTES treatment was defined as the rate of glutaminolysis.
Data are presented normalized to 106 cells as determined by Hoechst DNA
content assay.
Evaluating Mitochondrial Membrane Potential. JC-1 cell-permeable dye was
purchased from Life Technologies. HepG2/C3A cells were incubated with 50 μM
of troglitazone or rotenone for varying durations. To evaluate mitochondrial
membrane potential at each time point, cells were incubated with 5 μM JC-1
dye for 30 min, washed with PBS, and imaged by confocal microscopy on a
LSM700 (Zeiss). The JC-1 dye exhibits potential-dependent accumulation in
mitochondria, indicated by a fluorescence emission shift from 529 to 590 nm
due to the formation of J-aggregates. Consequently, mitochondrial de-
polarization is quantified by dividing red over green fluorescence intensity.
Metabolic Pathways and ATP Production. Glucose uptake, oxygen uptake, and
lactate production rates were measured by calculating the change in me-
tabolite concentration between the bioreactor in- and outflow as function of
perfusion rate and cell number as described above. Metabolic rates were
calculated assuming negligible contribution to oxygen uptake by fatty acid
oxidation and enzymatic activity. Low level of lipids in our culture medium
ensured that fatty acid uptake was 50-fold lower than glucose, whereas
glutamine contribution to the Krebs cycle was minor (Results). Periodic acid–
Schiff (PAS) staining showed no significant change in glycogen content
following 12-h exposure to the drugs (Fig. S1).
Based on these assumptions, oxidative phosphorylation flux was calculated
by dividing the oxygen uptake rate by six. We estimated 32 ATP molecules
generated by complete oxidation of one molecule of glucose. Glycolysis flux
was calculated by dividing lactate production rate by two, with maximal rate
defined by glucose uptake rate minus the oxidative phosphorylation flux. ATP
production in glycolysis was estimated to be two molecules per molecule of
glucose. We assumed that any glucose left over was directed toward lipo-
genesis, because the contribution of pentose phosphate pathway in non-
proliferating cells is minor (31). Finally, we assumed that excess lactate was
produced by glutaminolysis, and confirmed our assumption using offline
measurement of glutamine uptake (Fig. S2). ATP production in glutaminolysis
was estimated to be three molecules per molecule of lactate generated.
Statistical Analysis. Experiments were repeated 2–3 times with triplicate sam-
ples for each experimental condition. Data from representative experiments are
presented, whereas similar trends were seen in multiple trials. A parametric
two-tailed Student’s t test was used for calculating significant differences be-
tween groups. All n values represent the number of biological samples analyzed
per condition. All error bars indicate ± SD.
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SI Methods
Glycogen Quantification. Intracellular glycogen quantification was
carried out using PAS staining (Sigma-Aldrich). Briefly, HepG2/
C3A cells were treated for 12 h with 50 μM troglitazone, rotenone,
or vehicle control and fixed for 15 min in 4% PFA. Cells were
washed in distilled water and incubated for 5 min at room tem-
perature with the periodic acid solution. Next the cells were in-
cubated in Schiff’s reagent for 15 min at room temperature, washed
three times, counterstained in hematoxylin solution Gill no. 3 for
90 s at room temperature, and left to dry. Quantification was
performed using ImageJ software and presented as the ratio be-
tween PAS and hematoxylin staining.
Glutamine Uptake.Glutamine concentration was determined using
glutamine and glutamate determination kit (Sigma-Aldrich).
Bioreactors containing HepG2/C3A spheroids were set up as
described in the main text and perfused at 2 μL/min. Perfusate
samples were collected for 60 min for a total of 120 μL per
sample. Glutamine was quantified according to manufacturer
directions.
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Fig. S1. (A) Images of HepG2/C3A cells stained for PAS and hematoxylin following 12-h exposure to drugs. (B) Glycogen content was unchanged between the
three conditions.
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Fig. S2. (A) Glutamine uptake (outlet–inlet) in HepG2/C3A bioreactors exposed to 50 μM troglitazone or rotenone (dotted arrow). Rotenone exposure caused
an increase in glutamine uptake, whereas troglitazone increase was more muted. (B) Glutamine uptake rate, averaged over 3–6 h, during exposure to tro-
glitazone, rotenone, or control.
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